Alternative splicing and genomic structure of the Wilms tumor gene WT1
- PMID: 1658787
- PMCID: PMC52769
- DOI: 10.1073/pnas.88.21.9618
Alternative splicing and genomic structure of the Wilms tumor gene WT1
Abstract
The chromosome 11p13 Wilms tumor susceptibility gene WT1 appears to play a crucial role in regulating the proliferation and differentiation of nephroblasts and gonadal tissue. The WT1 gene consists of 10 exons, encoding a complex pattern of mRNA species: four distinct transcripts are expressed, reflecting the presence or absence of two alternative splices. Splice I consists of a separate exon, encoding 17 amino acids, which is inserted between the proline-rich amino terminus and the zinc finger domains. Splice II arises from the use of an alternative 5' splice junction and results in the insertion of 3 amino acids between zinc fingers 3 and 4. RNase protection analysis demonstrates that the most prevalent splice variant in both human and mouse is that which contains both alternative splices, whereas the least common is the transcript missing both splices. The relative distribution of splice variants is highly conserved between normal fetal kidney tissue and Wilms tumors that have intact WT1 transcripts. The ratio of these different WT1 mRNA species is also maintained as a function of development in the mouse kidney and in various mouse tissues expressing WT1. The conservation in structure and relative levels of each of the four WT1 mRNA species suggests that each encoded polypeptide makes a significant contribution to normal gene function. The control of cellular proliferation and differentiation exerted by the WT1 gene products may involve interactions between four polypeptides with distinct targets and functions.
Similar articles
-
RNA polymerase chain reaction detects different levels of four alternatively spliced WT1 transcripts in Wilms' tumors.Oncogene. 1992 Jul;7(7):1431-3. Oncogene. 1992. PMID: 1320246
-
Differentially spliced exon 5 of the Wilms' tumor gene WT1 modifies gene function.Anticancer Res. 1996 Mar-Apr;16(2):621-6. Anticancer Res. 1996. PMID: 8687106
-
WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant.Science. 1993 Dec 24;262(5142):2057-9. doi: 10.1126/science.8266105. Science. 1993. PMID: 8266105
-
The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor.FASEB J. 1993 Jul;7(10):896-903. FASEB J. 1993. PMID: 8393820 Review.
-
Wilms tumor and the WT1 gene.Exp Cell Res. 2001 Mar 10;264(1):74-99. doi: 10.1006/excr.2000.5131. Exp Cell Res. 2001. PMID: 11237525 Review.
Cited by
-
Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional target.Exp Cell Res. 2013 Mar 10;319(5):612-22. doi: 10.1016/j.yexcr.2012.12.021. Epub 2013 Jan 2. Exp Cell Res. 2013. PMID: 23291318 Free PMC article.
-
Genomic characterization of Wilms' tumor suppressor 1 targets in nephron progenitor cells during kidney development.Development. 2010 Apr;137(7):1189-203. doi: 10.1242/dev.045732. Development. 2010. PMID: 20215353 Free PMC article.
-
A novel Wilms tumor 1 (WT1) target gene negatively regulates the WNT signaling pathway.J Biol Chem. 2010 May 7;285(19):14585-93. doi: 10.1074/jbc.M109.094334. Epub 2010 Mar 10. J Biol Chem. 2010. PMID: 20220130 Free PMC article.
-
Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia.J Clin Med. 2020 Mar 16;9(3):802. doi: 10.3390/jcm9030802. J Clin Med. 2020. PMID: 32188030 Free PMC article. Review.
-
Genetics of cancer predisposition and progression.Clin Investig. 1993 Jun;71(6):488-502. doi: 10.1007/BF00180066. Clin Investig. 1993. PMID: 8353410 Review.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases